Clinical trials

Endothelial dysfunction
#Clinical trials #Endothelial dysfunction #Vicore Pharma

Vicore initiates clinical POC study of endothelial dysfunction 

Vicore Pharma, a Swedish clinical-stage pharmaceutical company unlocking the potential of angiotensin II type 2 receptor agonists (ATRAGs), has dosed its first patient with C21 in a clinical study of endothelial dysfunction.    Vicore Pharma states that results from the trial are expected in Q4, 2023. … Read More

#News

Gut microbiome
#Antibodies #Clinical trials #Destiny Pharma #Gut microbiome #Microbiology

Landmark trial data on successful gut colonisation

Data generated from a C. difficile infection (CDI) model study on the ability of M3 (NTCD-M3), a non-toxigenic C. difficile strain, shows successful gut colonisation following administration of fidaxomicin and has been peer-reviewed and published in Microbiology Spectrum. The paper by Destiny Pharma, a UK-based clinical stage biotechnology company focused… Read More

#News

#Clinical trials

Tirzepatide achieved up to 15.7% weight loss in trial 

Eli Lilly’s tirzepatide achieved superior weight loss compared to placebo at 72 weeks of treatment in results from SURMOUNT-2.   The study met both co-primary objectives and all key secondary objectives for tirzepatide compared to placebo for both estimands. Those taking tirzepatide lost up to 15.7% (34.4lb or… Read More

#News

#Age-related diseases (ARDs) #Ageing #AI #Biotechnology #Business #Clinical trials #mRNA

Podcast: The impact of technology on drug discovery

This is the latest episode of the free DDW narrated podcast, “The impact of technology on drug discovery”. It covers two articles written for Volume 23, Issue 2 – Spring 2022 of DDW. They are called “Talking Tech” and “Rejuvenation biotech: Can… Read More

#News

Scientist in laboratory
#AACR 2023 #Cancer research #Clinical trials #Immunotherapy #Oncology #Rare cancers

Trial results suggest new approaches to treat rare cancers

The AACR Annual Meeting’s second clinical trials plenary session, ‘Hope for Rare Cancers: Novel Targeted and Immunotherapy Agents’, highlighted promising studies that suggest new treatment approaches for rare cancers. First Hippo-YAP pathway inhibitor shows success in advanced solid tumours Timothy A Yap reported on a study… Read More

#Cancer Research #News #Trending News

#Clinical trials #Drug discovery

The need for greater diversity in clinical trials  

By Lucy Radley, Senior Vice President, Head of European Regulatory Development at ProPharma Group.  Clinical trials are, undoubtedly, an essential part of the drug development process, providing us with valuable information about the safety and efficacy of new treatments and therapies. However, despite their deep importance to the wellbeing of… Read More

#Exclusive Content

Real world data
#AI / data analytics / healthtech / informatics #BC Platforms #Clinical trials #Real world data #Regulatory

Enabling regulatory approval submissions with external control arms

This paid-for advertorial by BC Platforms appeared in DDW Volume 24 – Issue 2, Spring 2023 BC Platforms’ Global Data Partner Network provides patient-level, longitudinal, and geographically diverse real-world data and real-world evidence for use as external control arms in randomised human clinical trials, which can accelerate medicinal product regulatory… Read More

#Exclusive Content

#Brain cancer #Cancer research #Childhood cancer #Clinical trials #Paediatrics

CureSearch to fund Phase I clinical trial for paediatric brain cancer 

CureSearch for Children’s Cancer, a national non-profit with a mission to end childhood cancer by driving targeted and innovative research in an accelerated time frame, will fund a Phase I clinical trial to bring new therapies to paediatric brain cancer patients, including those with limited or no treatment options. Read More

#Cancer Research #News

Diversity
#Clinical trial design #Clinical trials #Diversity #Inato #Inclusivity #Investment #Oncology

$20 million in new funding to make clinical trials more inclusive

Clinical trial technology platform Inato, based in Paris, France, has closed a $20 million Series A funding from investors including Cathay Innovation, Obvious Ventures, La Maison and Top Harvest Capital. With the new funding, Inato will advance its diversity product offering to meet the new FDA requirements. The company will… Read More

#Business & Investment #News #Start-up Zone

#Autoimmune disease #Breast cancer #Cancer immunotherapy #Clinical trials #Immunotherapy #LAG-3

Phase II/III trial to assess LAG-3 immunotherapy in breast cancer 

Immutep, a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, has initiated AIPAC-003 (Active Immunotherapy, Eftilagimod Alpha, and Paclitaxel), an integrated Phase II/III trial to evaluate eftilagimod alpha (efti) in combination with paclitaxel for the treatment of metastatic HER2-neg/low breast cancer (MBC).  … Read More

#News

Clinical trial
#ABPI #Clinical trial design #Clinical trials #MHRA #UK

Biggest overhaul of UK clinical trial regulation for 20 years

A series of new measures will be introduced by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) to make it faster and easier to gain approval and run clinical trials in the UK. These changes represent the biggest overhaul in UK clinical trials regulation in… Read More

#News

In vitro diagnostics
#Clinical trials #EFPIA #EU #European Federation of Pharmaceutical Industries and Associations #In vitro #Pharmaceuticals #Regulatory

New EU in vitro regulations delaying clinical trials

New EU legislation designed to improve public health is delaying clinical trials and blocking access to new treatments for cancer and rare diseases, says the European Federation of Pharmaceutical Industries and Associations (EFPIA). The number of clinical trials delayed is expected to run into the hundreds, affecting up to 42,200… Read More

#News #Regulatory

Patient advocacy group
#Clinical trial design #Clinical trials #Decentralised clinical trials #Drug development #Patient centricity #Rare disease

Recruiting and retaining patients for successful drug development

Craig Stevens, Senior Patient Engagement Specialist, and Amanda Henkel, VP, Strategy from MEDiSTRAVA (an Inizio Company), delve into the challenges and opportunities that surround clinical trial design for rare diseases. The drug development process requires collaboration at all stages, and is particularly important in the rare disease setting, where in… Read More

#Exclusive Content

#Cancer research #Clinical trial design #Clinical trials #Drug discovery #Gene therapy #Oncology

Podcast: Key stories from the drug discovery industry

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Perhaps most interestingly this week, after previous caution over in vivo… Read More

#News

Dermatology patient
#Clinical trial design #Clinical trials #Decentralised clinical trials #ICON #LEO Pharma

LEO partners with ICON to offer patient-centric dermatology trials

LEO Pharma and ICON have formed a strategic partnership that will enable LEO to offer clinical trials within medical dermatology that are patient-centric and cost effective. The partnership will operate under the acronym of PACE, reflecting the requirement to move quickly to address today’s clinical development challenges. Read More

#News